Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
JAK inhibitor
Pharma
Incyte posts mixed Opzelura results in prurigo nodularis
As Incyte strives to push Opzelura into new dermatology indications, the company’s latest data drop in prurigo nodularis is a bit of a mixed bag.
Fraiser Kansteiner
Mar 10, 2025 11:23am
Incyte's JAK cream Opzelura slows while Leo competition looms
May 3, 2024 10:53am
Incyte's Opzelura scores in hidradenitis suppurativa study
Mar 11, 2024 1:58pm
With FDA nod for Crohn's, AbbVie wins 7th indication for Rinvoq
May 18, 2023 4:25pm
Leo Pharma scores in phase 3 trial for JAK inhibitor cream
Feb 13, 2023 3:05pm
Incyte still far from eczema cream Opzelura's pricing goal
Nov 1, 2022 11:30am
